Compare · BSX vs SI
BSX vs SI
Side-by-side comparison of Boston Scientific Corporation (BSX) and Shoulder Innovations Inc. (SI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 243.7x SI ($296.1M).
- Over the past year, BSX is down 51.1% and SI is down 6.4% - SI leads by 44.8 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 1 for SI).
- Both have 25 recent analyst ratings on file.
- Company
- Boston Scientific Corporation
- Shoulder Innovations Inc.
- Price
- $48.86+0.62%
- $14.13-0.49%
- Market cap
- $72.16B
- $296.1M
- 1M return
- -13.62%
- +9.62%
- 1Y return
- -51.14%
- -6.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 12
- 1
- Recent ratings
- 25
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest SI
- Shoulder Innovations to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form 10-Q filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
- CEO & Executive Chairman Ball Robert Joseph exercised 10,000 shares at a strike of $2.48, increasing direct ownership by 3% to 300,018 units (SEC Form 4)
- SEC Form DEF 14A filed by Shoulder Innovations Inc.
- SEC Form DEFA14A filed by Shoulder Innovations Inc.
- Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Initiates Full Commercial Launch of the InSet™ I-135RFX Humeral Stem
- Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026